Picture of iBio logo

IBIO iBio Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-10.22%
3m-28.47%
6m-85.43%
1yr-97.98%
Volume Change (%)
10d/3m-70.81%
Price vs... (%)
52w High-97.81%
50d MA-5.58%
200d MA-80.53%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-166.28%
Return on Equity-148.27%
Operating Margin-41466%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Jun 202430th Jun 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of iBio EPS forecast chart

Profile Summary

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Directors

Last Annual
June 30th, 2023
Last Interim
December 31st, 2023
Incorporated
April 17th, 2008
Public Since
August 18th, 2008
No. of Shareholders
27
No. of Employees
26
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
3,484,266

IBIO Share Price Performance

Upcoming Events for IBIO

Q3 2024 Ibio Inc Earnings Release

Similar to IBIO

FAQ